SWOG clinical trial number
CTSU/CTN0702

A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma

Closed
Phase
Abbreviated Title
Single Auto Transplant w/ or w/o Consolidation vs. Tandem Auto Transplant w/ Len Maintenance for MM
Activated
03/15/2010
Closed
11/15/2013
Participants
CTSU

Research committees

Myeloma

Treatment

Filgrastim Melphalan CC-5013 (Lenalidomide) Bortezomib

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2019

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

E Stadtmauer;M Pasquini;B Blackwell;P Hari;A Bashey;S Devine;Y Efebera;S Ganguly;C Gasparetto;N Geller;M Horowitz;J Koreth;K Knust;H Landau;C Brunstein;P McCarthy;C Nelson;M Qasilbash;N Shah;D Vesole;R Vij;D Vogl;S Giralt;G Somlo;A Krishnan Journal of Clinical Oncology Mar 1;37(7):589-597

PMid: PMID30653422 | PMC number: PMC6553842

Other Clinical Trials

SWOG Clinical Trial Number
S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Research Committee(s)
Myeloma
Activated
12/01/2023
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2209

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Research Committee(s)
Myeloma
Activated
05/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
S2005

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Research Committee(s)
Myeloma
Activated
06/24/2021
Accrual
8%
Open
Phase